% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Leichsenring:181957,
      author       = {J. Leichsenring and V. Vladimirova and C. Solbach and T.
                      Karn and B. Ataseven and B. V. Sinn and J. Barinoff and V.
                      Müller and J.-U. Blohmer and C. Schem and K. Engels and F.
                      Marmé and A. Fisseler-Eckhoff and P. A. Fasching and E.
                      Stickeler and M. van Mackelenbergh and C. Denkert and A.
                      Stenzinger and S. Loibl and S. Gröschel$^*$},
      title        = {{EVI}1 expression in early-stage breast cancer patients
                      treated with neoadjuvant chemotherapy.},
      journal      = {BMC cancer},
      volume       = {22},
      number       = {1},
      issn         = {1471-2407},
      address      = {Heidelberg},
      publisher    = {Springer},
      reportid     = {DKFZ-2022-02327},
      pages        = {1040},
      year         = {2022},
      note         = {#LA:A380#},
      abstract     = {Overexpression of the EVI1 (ecotropic viral integration
                      site 1) oncogene has recently been implicated as a
                      prognostic factor in breast cancer (BC), particularly in
                      triple-negative BC (TNBC). In this study we aimed to
                      investigate frequency and clinical relevance of EVI1
                      expression in newly diagnosed BC treated with neoadjuvant
                      chemotherapy.EVI1 expression was determined by
                      immunohistochemistry using H-score as a cumulative
                      measurement of protein expression in pretherapeutic biopsies
                      of BC patients treated with anthracycline/taxane based
                      neoadjuvant chemotherapy within the GeparTrio trial. EVI1
                      was analyzed as a continuous variable and dichotomized into
                      low or high based on median expression. Endpoints were
                      pathological complete response (pCR), disease-free survival
                      (DFS) and overall survival (OS).Of the 993 tumors analyzed,
                      882 had available subtype information: $50.8\%$ were HR +
                      /HER2-, $15\%$ HR + /HER2 + , $9.8\%$ HR-/HER2 + , and
                      $24.5\%$ TNBC. Median EVI1 H-score was 112.16 (range
                      0.5-291.4). High EVI1 expression was significantly
                      associated with smaller tumor size (p = 0.002) but not with
                      BC subtype. Elevated EVI1 levels were not significantly
                      associated with therapy response and survival in the entire
                      cohort or within BC subtypes. However, TNBC patients with
                      high EVI1 showed a trend towards increased pCR rates
                      compared to low group $(37.7\%$ vs $27.5\%,$ p = 0.114; odds
                      ratio 1.60 $(95\%CI$ 0.90-2.85, p = 0.110) and numerically
                      better DFS (HR = 0.77 $[95\%CI$ 0.48-1.23], log-rank p =
                      0.271) and OS (HR = 0.76 $[95\%$ 0.44-1.31], log-rank p =
                      0.314) without reaching statistical significance.EVI1 was
                      not associated with response to neoadjuvant therapy or
                      patient survival in the overall cohort. Further analyses are
                      needed to verify our findings especially in the pathological
                      work-up of early-stage HER2-negative BC
                      patients.NCT00544765.},
      keywords     = {Breast cancer (Other) / EVI1 (Other) / Neoadjuvant
                      chemotherapy (Other)},
      cin          = {A380},
      ddc          = {610},
      cid          = {I:(DE-He78)A380-20160331},
      pnm          = {311 - Zellbiologie und Tumorbiologie (POF4-311)},
      pid          = {G:(DE-HGF)POF4-311},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:36195836},
      doi          = {10.1186/s12885-022-10109-1},
      url          = {https://inrepo02.dkfz.de/record/181957},
}